R. Angell

发表

Progress towards a public chemogenomic set for protein kinases and a call for contributions

Stephen J. Capuzzi, T. Willson, Mathias Frederiksen, 2017, bioRxiv.

Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry

R. Angell, R. Ketteler, M. Marsh, 2019, Viruses.

Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.

P. Bamborough, R. Angell, A. Walker, 2008, Bioorganic & medicinal chemistry letters.

Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases.

R. Angell, Michela Mazzon, S. Oxenford, 2019 .

Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism.

R. Angell, O. Singh, K. Biggadike, 2000, Journal of medicinal chemistry.

Asymmetrically Substituted Quadruplex-Binding Naphthalene Diimide Showing Potent Activity in Pancreatic Cancer Models.

R. Angell, S. Neidle, W. Wilson, 2020, ACS medicinal chemistry letters.

The Prophylaxis and Treatment with Antiviral Agents of Respiratory Syncytial Virus Infections

R. Angell, P. Najarro, K. Powell, 2012, Antiviral chemistry & chemotherapy.

Development of a Fluorescence Intensity Assay for the Mitotic Serine/Threonine Protein Kinase Aurora-A

R. Angell, S. Campbell, Andrew F. Slatter, 2013, Journal of biomolecular screening.

N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.

P. Bamborough, R. Angell, L. Fazal, 2007, Bioorganic & medicinal chemistry letters.

The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors

Sebastian Lambert, R. Angell, N. Meanwell, 2014, Protein science : a publication of the Protein Society.

BIROn - Birkbeck Institutional Research Online Regulation of metastasis suppressor NME1 by a key metabolic cofactor coenzyme A. Redox

Pallavi Arora, R. Angell, Y. Tsuchiya, 2021 .

Getting to Know Dengue Polymerase: The Development of Optimised Assay Conditions Using Stability Screening

R. Angell, Alice Hooper, S. Oxenford, 2019 .

Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.

Paul Bamborough, Penny A. Smee, P. Bamborough, 2008, Bioorganic & medicinal chemistry letters.

N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.

R. Angell, P. Rowland, M. Cichy-Knight, 2007, Bioorganic & medicinal chemistry letters.

A New and Simple Methodology for the Construction of Geometrically Pure Double Bonds

R. Angell, P. Parsons, A. Naylor, 1993 .

Enantioselective synthesis of homoallylic alcohols using(E)-but-2-enyl-trichlorosilane and chiral diamines

R. Angell, A. Barrett, S. Swallow, 1997 .

A novel approach to the histrionicotoxin framework

R. Angell, P. Parsons, A. Naylor, 1993 .

Structures of S. aureus thymidylate kinase reveal an atypical active site configuration and an intermediate conformational state upon substrate binding

D. Stammers, A. Hawkins, C. Nichols, 2006, Protein science : a publication of the Protein Society.

Substituted Naphthalenediimide Compounds Bind Selectively to Two Human Quadruplex Structures with Parallel Topology.

Stephan A. Ohnmacht, R. Angell, S. Neidle, 2020, ACS medicinal chemistry letters.

Regulation of metastasis suppressor NME1 by a key metabolic cofactor coenzyme A

I. Gout, Pallavi Arora, R. Angell, 2021, Redox biology.

Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.

Paul Bamborough, Penny A. Smee, P. Bamborough, 2008, Bioorganic & medicinal chemistry letters.

Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.

Paul Bamborough, P. Bamborough, R. Angell, 2008, Bioorganic & medicinal chemistry letters.

Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases

R. Angell, Michela Mazzon, S. Oxenford, 2019, Biology Open.

Novel Glucocorticoid Antedrugs Possessing a 21-(γ-Lactone) Ring.

R. Angell, S. Lynn, K. Biggadike, 2010 .

Novel glucocorticoid antedrugs possessing a 21-(?-lactone) ring

R. Angell, S. Lynn, K. Biggadike, 2002 .

Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion.

Sara M. Johnson, C. Scott, R. Angell, 2021, Journal of medicinal chemistry.

A small molecule PI3Kα activator for cardioprotection and neuroregeneration

Ralitsa R. Madsen, Roger L. Williams, P. Hawkins, 2023, Nature.

Cycloadditions of 1,3-oxazolium-4-olates (isomünchnones) by rhodium(II)-induced decomposition of α-diazocarbonyl derivatives of (5R)- and (5S)-phenyloxazin-3-one as a chiral template

R. Angell, L. Harwood, H. Finch, 1997 .

Novel Chiral Templates for 1,3-Oxazolium-4-olate (Isomünchnone) Cycloadditions: (5 R)- and (5 S)-Phenyloxazin-2,3-dione

M. Drew, R. Angell, L. Harwood, 1997 .

Evasion of a Human Cytomegalovirus Entry Inhibitor with Potent Cysteine Reactivity Is Concomitant with the Utilization of a Heparan Sulfate Proteoglycan-Independent Route of Entry

R. Angell, D. Depledge, M. Reeves, 2020, Journal of Virology.

Tetrahydroisoquinolines affect the whole-cell phenotype of Mycobacterium tuberculosis by inhibiting the ATP-dependent MurE ligase

R. Angell, H. Hailes, S. Bhakta, 2015, The Journal of antimicrobial chemotherapy.

Condensed heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of, inter alia, rheumatoid arthritis.

P. Bamborough, R. Angell, Timothy Longstaff, 2003 .

Conformational preferences in 2-alkyl, 2-alkanoyl and 2-aroyl-2-oxo-1,3,2-oxazaphosphorinanes

R. Angell, K. Afarinkia, Clare Jones, 2001 .

Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.

P. Bamborough, R. Angell, A. Walker, 2008, Bioorganic & medicinal chemistry letters.